Dong-A ST Signs License-out Deal with Polifarma of Türkiye for NESP® Biosimilar DA-3880
9.11.2022 17:00:00 EET | Business Wire | Press release
Dong-A ST (Min Young Kim, President and CEO) (KRX: 170900) announced that they signed an exclusive license-out and supply agreement on November 4, 2022, with Polifarma (Mehmet Asri, CEO) for NESP® biosimilar DA-3880.
According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 in Türkiye, Brazil, and Mexico to Polifarma. Dong-A ST will receive upfront and developmental/commercial milestone payments and will exclusively supply the finished product through STgen Bio, an affiliated Bio CDMO of Dong-A Socio Holdings. Meanwhile, Polifarma will be responsible for the development and commercialization in Türkiye, Brazil, and Mexico.
The details of the upfront, milestone payments, and supply profit structure remain undisclosed as per the consensus between both parties.
“DA-3880” is an ARANESP®/NESP® biosimilar for the treatment of anemic patients with chronic renal failure or those undergoing chemotherapy. Dong-A ST signed a license-out agreement with Sanwa Kagaku Kenkyusho in 2014 for the development and commercialization of DA-3880 in Japan. After regulatory approval from PMDA (Pharmaceuticals and Medical Devices Agency, Japan) in 2019, DA-3880 has been successfully commercialized in the Japanese market, making it one of the bestsellers among darbepoetin alfa biosimilar products.
Polifarma is a Türkiye pharmaceutical company with 100% domestic capital and 36 years of experience. It has established actual export records of 586 drugs to over 70 countries, including the US, Europe, Brazil, and Mexico. As the most well-known, and most preferred, hospital products brand in Türkiye, Polifarma’s goal is to maintain its lead in the Türkiye market and become one of the biggest global leaders by sustaining its quality and technological superiority.
Jae Hong Park (President and CSO of Dong-A ST) said, “This agreement provides an opportunity for Dong-A ST to introduce DA-3880 beyond the Japanese market and into the global biosimilar market including Türkiye and South & Central America. Dong-A ST will commit to expanding its global market presence by showcasing our biosimilar R&D and overseas business capabilities.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005472/en/
Contact information
Dong-A ST CO., Ltd
Jin-Seok Jeong
+82-2-920-8212
treadwheel@donga.co.kr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpaca Launches German Equities Trading via Deutsche Börse Xetra21.7.2026 14:00:00 EEST | Press release
Alpaca, a global leader in agent-first brokerage infrastructure, today announced that its broker partners can now offer trading in German equities through Deutsche Börse Xetra, providing access to one of Europe’s largest equity markets. The launch marks the first phase of Alpaca’s broader global equities initiative. In the coming months, Alpaca expects to roll out access to additional major international exchanges, including Hong Kong Stock Exchange, London Stock Exchange, Saudi Exchange, Euronext Paris, and Korea Exchange, with additional markets planned. Germany is the largest economy in Europe and the third largest in the world, behind the United States and China. Through Xetra, Alpaca’s broker partners can offer access to hundreds of German equities, including shares in companies such as SAP, Siemens, Allianz, BMW, Deutsche Bank, Adidas, and Bayer, across sectors including technology, manufacturing, financial services, and healthcare. "Investors increasingly expect access beyond U.
SIAL Paris 2026: the Event That Sheds Light on and Accelerates the Global Agri-food Industry21.7.2026 13:10:00 EEST | Press release
With just a few months to go until SIAL Paris 2026 (17–21 October, Paris Nord Villepinte), the trade fair has unveiled the findings of its new SIAL Insights 2026 report, an international analysis identifying ten major trends set to bring about lasting change to food markets and consumer behavior. Compiled using exclusive data from Kantar Food 360™, Circana and ProtéinesXTC, the report highlights a more personalised, functional and experiential approach to food, whilst revealing the new trade-offs consumers are making in the face of economic, health and environmental challenges. The 10 key insights into food in 2026 1. Healthy eating: fuel for a high-performing body Consumers are seeking measurable benefits: protein, fiber, energy, immunity or digestive health. 2. The ‘gut brain’: food for mental wellbeing Sleep, stress management, hormonal balance and cognitive performance now influence dietary choices. 3. Pleasure as a conscious experience Premium taste experiences, bold flavors and c
Sagepath Reply Recognized in the 2026 Gartner® Market Guide for Strategic Website Agencies21.7.2026 11:00:00 EEST | Press release
Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. This marks the third time Sagepath Reply has been named in the Market Guide, following its previous inclusions in 2023 and 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721481392/en/ Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. Gartner, a company delivering actionable, objective insight to executives and their teams, defines strategic website agencies as “service providers dedicated to developing website strategies that deliver relevant digital experiences to external audiences. These agencies bundle their strategic marketing services with an array of complementary offerings to support their clients’ needs around website design, development, search value and co
ClickHouse Announced as Principal Partner & Front of Shirt Sponsor of Fulham Football Club21.7.2026 11:00:00 EEST | Press release
Fulham Football Club is proud to announce ClickHouse, a global technology company specialising in real-time analytics, data infrastructure and AI applications, as its newest Principal Partner and Front of Shirt Sponsor of the Men’s First Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721902779/en/ ClickHouse announced as Principal Partner and Front of Shirt Sponsor of Fulham Football Club This multi-year partnership will see ClickHouse take pride of place on the front of the Men’s First Team home, away and third kits. ClickHouse will also feature across Craven Cottage, the Club’s digital channels, matchday assets and a range of supporter-facing experiences throughout the partnership. The Fulham FC home kit will be released on Thursday 23rd July 2026, keep an eye on the Club’s Instagram for updates. Our collaboration reflects Fulham’s continued focus on innovation, performance and delivering engaging experiences for
European Commission Approves Crysvita ® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union21.7.2026 10:00:00 EEST | Press release
Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeletal development from an early age. Earlier diagnosis and treatment are considered important in XLH given the potential impact of the disease on skeletal development during infancy and childhood. XLH is a rare, progressive, lifelong genetic disease characterised by phosphate wasting that can impair bone mineralisation from an early age, leading to skeletal deformities, impaired growth and other serious complications. Clinical manifestations of XLH can emerge during infancy and early childhood, with pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom